AHA 2024 Figure 1 (corrected 2025), wording as printed. Shows your position in the figure, not a treatment decision. Nothing is saved or sent.
Adapted from AHA 2024 Figure 1, corrected.
or
Yes
No
Long-term management by risk level: Kawasaki Coronary Z-Scores.
| Agent | Dose |
|---|---|
| IVIG | 2 g/kg IV over 8–12 h. Consider slower infusion in KD shock or myocardial dysfunction, and lean body mass dosing in obesity. |
| Aspirin | 30 to 50 mg/kg per d PO divided every 6 h (used in many centers; the dose is under prospective study), then 3–5 mg/kg per d PO once afebrile for 48–72 h. Not with NSAIDs. |
| Class | Recommendation | LOE |
|---|---|---|
| I | Complete KD criteria, or meeting the algorithm criteria for incomplete KD: high-dose IVIG (2 g/kg as a single intravenous infusion) within 10 days of illness onset, as soon as possible after diagnosis. | A |
| IIa | Reasonable after the 10th day of illness with persistent fever without other explanation, or coronary artery abnormalities together with ongoing systemic inflammation (ESR or CRP elevated; CRP >3.0 mg/dL). | B |
| III | IVIG generally should not be given beyond the tenth day of illness in the absence of fever, significant elevation of inflammatory markers, or coronary artery abnormalities. | C |
Doses as printed in AHA 2024 Table 3; check with your KD team or pharmacy. AHA 2024 Diagnosis Key Point 5: patients with z ≥2.5 at diagnosis or age <6 months “should be considered for intensification of primary therapy”. Its Treatment Key Point 1 and text say intensification “may benefit” high-risk patients (baseline z ≥2.5, infants <6 months, or high risk on the Son score, on Kawasaki Coronary Z-Scores), and that efficacy data from randomized controlled trials are lacking.
| Agent | Dose, as printed |
|---|---|
| Intensification, IVIG-resistant or high-risk patients | |
| Prednisoloneas per RAISE | IV, 2 mg/kg per d divided every 8 h for 5 d (maximum 60 mg/d) while hospitalized; then PO prednisolone 2 mg/kg per d divided every 8 h; slow tapering over 15 d (maximum 30 mg/dose) once CRP normalized. Famotidine is given to prevent gastric ulcer.Unresolved: 60 mg/d divided every 8 h is 20 mg per dose, yet the taper prints a maximum of 30 mg/dose and no taper frequency. The RAISE abstract gives only 2 mg/kg per day given over 15 days after CRP normalised abstract. AHA 2024: the RAISE results are “compelling, but have not been validated in a non-Japanese population”. |
| Methylprednisoloneas per North American studies | IV, 2 mg/kg per d divided every 12 h for 5 d (maximum 60 mg/d) while hospitalized; then PO prednisone 2 mg/kg per d divided every 12 h; once CRP <1 mg/dL, corticosteroids are tapered over 2–4 wk with the dose cut in half every 5 d. Famotidine is given to prevent gastric ulcer. |
| Infliximab | IV, 10 mg/kg given over 2 h.The dose in KIDCARE, a randomized comparison with second IVIG abstract. AHA 2017 Table 6 printed 5 mg/kg, the dose of an earlier phase I randomized trial. |
| Etanercept | SC, 0.8 mg/kg weekly ×3 doses. |
| Additional therapy for refractory disease | |
| Cyclosporine | PO, 5 mg/kg per d divided every 12 h; check 2 h level after 3rd dose (goal of 300–600 ng/mL); start to taper (by 10% every 3 d) once patient afebrile, clinically improving, and CRP ≤1.0 mg/dL or 10 d of therapy, whichever is longer. Use Neoral; Mg protein complex (133 mg) once daily; not with statins. |
| Anakinra | IV/SC, 10 mg/kg per d (IV divided q12 h preferred to SC) while hospitalized; wean once ready for discharge (5 mg/kg per d for 1 d, then stop).AHA 2024 cites 2–11 mg/kg per day, IV or SC, in 22 patients with coronary aneurysms (Yang 2022, phase I/IIa abstract), and 2 to 6 mg/kg per day SC in 16 IVIG-resistant patients (Koné-Paut 2021, phase II abstract). AHA 2017 Table 6 printed 2–6. AHA 2024: no data regarding efficacy in patients with coronary abnormalities. |
| Second dose of IVIG | IV, 2 g/kg given over 8–12 h. Increased risk of hemolytic anemia with A, B, and AB blood types. |
| Cyclophosphamide | Consult rheumatology. Table 3 prints: IV, 10 mg/kg per d in 1 or 2 doses; adequate hydration needed; consider rheumatology consult. It prints no duration.How the series AHA 2024 cites gave it: Halyabar 2021. AHA 2024: in giant aneurysms continuing to progress despite IVIG and other adjunctive anti-inflammatory therapies, cyclophosphamide “has been used in patients with KD who are refractory to multiple other therapies”, usually in consultation with rheumatologists. |
Graded rows on these options, from AHA 2017 (pp. e947, e949). They postdate RAISE and predate KIDCARE and the anakinra studies. Class and level as published.
| Class | Recommendation | LOE |
|---|---|---|
| IIb | High-risk patients, when identifiable before treatment: a longer course of corticosteroids (eg, tapering over 2–3 weeks) with IVIG 2 g/kg and aspirin may be considered. | B |
| III | Single-dose pulse methylprednisolone should not be given with IVIG as routine primary therapy. | B |
| IIa | IVIG-resistant: a second dose of IVIG (2 g/kg) is reasonable with persistent or recrudescent fever at least 36 hours after the end of the first infusion. | B |
| IIb | IVIG-resistant: high-dose pulse steroids (usually methylprednisolone 20–30 mg/kg IV for 3 days, with or without an oral prednisone taper) may be considered as an alternative to a second infusion, or for retreatment.AHA 2017 contradicts itself here: its Table 6 footnote says pulsed high-dose steroid treatment is not recommended. | B |
| IIb | Retreatment: a longer (eg, 2–3 weeks) tapering course of prednisolone or prednisone with IVIG 2 g/kg and aspirin may be considered. | B |
| IIb | IVIG-resistant: infliximab (5 mg/kg) may be considered as an alternative to a second infusion or corticosteroids. | C |
| IIb | Refractory, after a second infusion, infliximab or a course of steroids has failed: cyclosporine may be considered. | C |
| IIb | Highly refractory: immunomodulatory monoclonal antibody therapy (except TNF-α blockers), cytotoxic agents, or (rarely) plasma exchange may be considered. | C |
AHA 2024 carries no class of recommendation or level of evidence, so these rows are from AHA 2017 (pp. e943, e945). Paraphrased; class and level as published.
| Class | Recommendation | LOE |
|---|---|---|
| IIa | Moderate- (30–50 mg/kg/d) to high-dose (80–100 mg/kg/d) aspirin is reasonable until afebrile, although there is no evidence that it reduces coronary artery aneurysms. | C |
| I | Echocardiography when the diagnosis is considered; unavailability or technical limitations should not delay treatment. | B |
| I | Image the coronary arteries, with luminal dimensions normalized as z scores adjusted for body surface. | B |
International Kawasaki Disease Registry, 1651 patients with an aneurysm (maximum z ≥2.5). The paper reports complications almost entirely confined to maximum z ≥10, where risk kept rising over time. The Results report one exception: a patient with a medium aneurysm (maximum z 8.5, all 4 branches) who died of chronic ischemia 6 months after the acute phase.
A prognosis table, not a risk calculator. The bands use z alone and drop the AHA 8 mm rule, so do not map onto AHA risk levels.
| Band | Small2.5≤Z<5 | Medium5≤Z<10 | LargeZ≥10 |
|---|---|---|---|
| Patients | 854 | 357 | 440 |
| Median follow-up, y (IQR) | 1.2 (0.4–3.4) | 2.8 (1.0–6.3) | 5.2 (1.9–8.9) |
| Had angiography or MRI | 1% | 5% to 8% | ≈50% |
| 10-year cumulative incidence per patient (± standard error) | |||
| Luminal narrowing (>50%, on angiography) | none reported | none reported | 20±3% |
| Coronary artery thrombosis | none reported | none reported | 18±2% |
| Composite major adverse cardiac complications | none reported | 1 patient | 14±2% |
| Normalization of luminal diameter to Z <2.5, 10 years (± as printed) | 99±4% as printed | 92±1% | 57±3% |
| Per patient (± standard error) | Small | Medium | Large |
|---|---|---|---|
| Coronary artery interventions | none reported | none reported | 10±2% |
| Myocardial infarction | none reported | none reported | 5±2% |
| Death from cardiac causes or heart transplantation | none reported | 1 patient (the same one) | 2±1% |
Criteria selector, pathway, doses, outcomes by coronary z band
AHA 2024 says the diagnostic criteria have not changed. As printed, these differ. Feature numbering differs too, so this page never cites a feature by number.
| Item | AHA 2017 (Table 3, Figure 3) | AHA 2024 (Figure 1, corrected) |
|---|---|---|
| Rash | Maculopapular, diffuse erythroderma, or erythema multiforme-like | Polymorphous rash |
| Hands and feet | Erythema and edema in the acute phase and/or periungual desquamation in the subacute phase | Palmar and plantar erythema, usually with swelling; desquamation described as what follows |
| Nodes | ≥1.5 cm diameter, usually unilateral | Usually unilateral, cluster of nodes ≥1.5 cm |
| Exclusion | In prose and a figure footnote | A bullet in the list |
| Incomplete, children | Fever ≥5 days and 2 or 3 criteria | Prolonged unexplained fever and 2–3/5 |
| Incomplete, infants | Fever for ≥7 days without other explanation | Unexplained fevers 7 d |
| Platelets | ≥450,000 after the 7th day of fever | ≥450,000 |
| Echo routes | Z ≥2.5; aneurysm observed; or ≥3 other suggestive features | Z ≥2.5; or ≥3 other suggestive features |
| Laboratory-negative | CRP <3.0 mg/dL and ESR <40 mm/hr: serial re-evaluation if fevers persist, echo if typical peeling develops | No such branch; the arm goes to the KD team decision |
| Incomplete, outcome | Treat box (AHA 2017 Figure 3) | Decision to treat per KD team? |
| High-risk features | Not in the figure | ≤6 mo of age; LAD or RCA z-score ≥2.5 on baseline echo |